Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России, Москва, Россия kasimovah@inbox.ru
Список исп. литературыСкрыть список 1. Андрющенко А.В. Распространенность и структура психических расстройств в общей медицине. Психические расстройства в общей медицине. 2011; 1: 14–28. / Andriushchenko A.V. Rasprostranennost' i struktura psikhicheskikh rasstroistv v obshchei meditsine. Mental Disorders in General Medicine. 2011; 1: 14–28. [in Russian] 2. Арпентьева М.Р. Жизнеутверждение и нравственно-психологические аспекты здоровья и болезней. Калуга: КГУ, 2017. / Arpent'eva M.R. Zhizneutverzhdenie i nravstvenno-psikhologicheskie aspekty zdorov'ia i boleznei. Kaluga: KGU, 2017. [in Russian] 3. Арпентьева М.Р. Клинико-психологическое консультирование в развитии жизнеутверждающего потенциала личности. Клин. и медицинская психология: исследования, обучение, практика. 2016; 1 (11). http://medpsy.ru/climp / Arpent'eva M.R. Kliniko-psikhologicheskoe konsul'tirovanie v razvitii zhizneutverzhdaiushchego potentsiala lichnosti. Klin. i meditsinskaia psikhologiia: issledovaniia, obuchenie, praktika. 2016; 1 (11). http://medpsy.ru/climp [in Russian] 4. Бажин Е.Ф., Гнездилов A.B. Психофармакологические и психокоррекционные аспекты реабилитации онкологических больных. Реабилитация онкологических больных. М., 1988; с. 46–65. / Bazhin E.F., Gnezdilov A.B. Psikhofarmakologicheskie i psikhokorrektsionnye aspekty reabilitatsii onkologicheskikh bol'nykh. Reabilitatsiia onkologicheskikh bol'nykh. M., 1988; s. 46–65. [in Russian] 5. Бухтояров О.В., Самарин Д.М. Психогенный канцерогенез. Здоровье и образование в XXI веке. 2010; 12 (1). https://cyberleninka.ru/article/n/psihogennyy-kantserogenez / Bukhtoiarov O.V., Samarin D.M. Psikhogennyi kantserogenez. Zdorov'e i obrazovanie v XXI veke. 2010; 12 (1). https://cyberleninka.ru/article/n/psihogennyy-kantserogenez [in Russian] 6. Вагайцева М.В., Чулкова В.А., Карпова Э.Б., Леоненкова С.А. Психологические исследования в онкологии. Вестн. Южно-Уральского гос. ун-та. Сер.: Психология. 2015; 8 (3): 28–35. / Vagaitseva M.V., Chulkova V.A., Karpova E.B., Leonenkova S.A. Psikhologicheskie issledovaniia v onkologii. Vestn. Iuzhno-Ural'skogo gos. un-ta. Ser.: Psikhologiia. 2015; 8 (3): 28–35. [in Russian] 7. Ганич М.К. Психологические факторы, влияющие на возникновение и течение онкологического заболевания. Научное обозрение. Сер. 2: Гуманитарные науки. 2016; 2: 77–80. / Ganich M.K. Psikhologicheskie faktory, vliiaiushchie na vozniknovenie i techenie onkologicheskogo zabolevaniia. Nauchnoe obozrenie. Ser. 2: Gumanitarnye nauki. 2016; 2: 77–80. [in Russian] 8. Демин Е.В., Гнездилов А.В., Чулкова В.А. Психоонкология: становление и перспективы развития. 2011; 57 (1): 86–91. / Demin E.V., Gnezdilov A.V., Chulkova V.A. Psikhoonkologiia: stanovlenie i perspektivy razvitiia. 2011; 57 (1): 86–91. [in Russian] 9. Жаринов Г.М., Некласова Н.Ю., Богомолов О.А., Анисимов В.Н. Влияние некоторых психологических и социальных факторов на течение и результаты лечения онкологических больных. Практическая онкология. 2016; 17 (4): 256–70. / Zharinov G.M., Neklasova N.Iu., Bogomolov O.A., Anisimov V.N. Vliianie nekotorykh psikhologicheskikh i sotsial'nykh faktorov na techenie i rezul'taty lecheniia onkologicheskikh bol'nykh. Prakticheskaia onkologiia. 2016; 17 (4): 256–70. [in Russian] 10. Зельнер В. Психика и рак. Могут ли психосоциальные факторы вызывать рак или оказывать влияние на течение онкологического заболевания? Консультативная психология и психотерапия. 2014; 1: 24–39. / Zel'ner V. Psikhika i rak. Mogut li psikhosotsial'nye faktory vyzyvat' rak ili okazyvat' vliianie na techenie onkologicheskogo zabolevaniia? Konsul'tativnaia psikhologiia i psikhoterapiia. 2014; 1: 24–39. [in Russian] 11. Зотов П.Б. Суицидальное поведение онкологических больных. Отношение врачей-онкологов. Суицидология. 2011; 4 (5): 18–25. / Zotov P.B. Suitsidal'noe povedenie onkologicheskikh bol'nykh. Otnoshenie vrachei-onkologov. Suitsidologiia. 2011; 4 (5): 18–25. [in Russian] 12. Иванов С.В. Вальдоксан при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике. Психиатрия и психофармакотерапия. 2009; 6: 15–9. / Ivanov S.V. Val'doksan pri terapii umerennykh i tiazhelykh depressii nepsikhoticheskogo urovnia v ambulatornoi i gospital'noi praktike. Psychiatry i Psychopharmacotherapy. 2009; 6: 15–9. [in Russian] 13. Иванов С.В. Депрессивные расстройства в онкологии (обзор). Журн. неврологии и психиатрии. 2012; 11. Вып. 2; с. 104–9. / Ivanov S.V. Depressivnye rasstroistva v onkologii (obzor). Zhurn. nevrologii i psikhiatrii. 2012; 11. Vyp. 2; s. 104–9. [in Russian] 14. Кайгородова Н.З., Любимова О.М., Петрова В.Д., Парамонова О.В. Некоторые психологические характеристики онкобольных в связи с особенностями психокорекционной работы. Известия Алтайского гос. ун-та. 2014; 2 (2, 82): 22–6. / Kaigorodova N.Z., Liubimova O.M., Petrova V.D., Paramonova O.V. Nekotorye psikhologicheskie kharakteristiki onkobol'nykh v sviazi s osobennostiami psikhokorektsionnoi raboty. Izvestiia Altaiskogo gos. un-ta. 2014; 2 (2, 82): 22–6. [in Russian] 15. Калашникова В.Ф., Браш Н.Г., Кадышев Д.А. Психические расстройства у пациентов с онкологическими заболеваниями: анализ проблемы и общие рекомендации (по данным диспансерного отделения АРПБ). Амурский мед. журн. 2016; 2 (14): 78–80. / Kalashnikova V.F., Brash N.G., Kadyshev D.A. Psikhicheskie rasstroistva u patsientov s onkologicheskimi zabolevaniiami: analiz problemy i obshchie rekomendatsii (po dannym dispansernogo otdeleniia ARPB). Amurskii med. zhurn. 2016; 2 (14): 78–80. [in Russian] 16. Березанцев А.Ю. и др. Клинические и психосоциальные аспекты реабилитации женщин с онкологической патологией репродуктивной системы. Психические расстройства в общей медицине. 2011; 1: 28–33. / Berezantsev A.Iu. i dr. Klinicheskie i psikhosotsial'nye aspekty reabilitatsii zhenshchin s onkologicheskoi patologiei reproduktivnoi sistemy. Mental Disorders in General Medicine. 2011; 1: 28–33. [in Russian] 17. Комкова Е.П. Психофармакотерапия – неотъемлемый блок в лечении онкологических заболеваний. Психические расстройства в общей медицине. 2012; 2: 8–12. / Komkova E.P. Psikhofarmakoterapiia – neot"emlemyi blok v lechenii onkologicheskikh zabolevanii. Mental Disorders in General Medicine. 2012; 2: 8–12. [in Russian] 18. Кукшина А.А., Верещагина Д.А. Особенности психоэмоционального состояния и психотерапевтические подходы в реабилитации онкологических больных. Физиотерапия, бальнеология и реабилитация. 2013; 5: 28–34. / Kukshina A.A., Vereshchagina D.A. Osobennosti psikhoemotsional'nogo sostoianiia i psikhoterapevticheskie podkhody v reabilitatsii onkologicheskikh bol'nykh. Fizioterapiia, bal'neologiia i reabilitatsiia. 2013; 5: 28–34. [in Russian] 19. Лаптева Е.В., Жирков А.М. Когнитивные компоненты эмоциональных нарушений у онкогематологических больных. Вестн. Южно-Уральского гос. ун-та. Сер.: Психология. 2015; 8 (4): 52–60. / Lapteva E.V., Zhirkov A.M. Kognitivnye komponenty emotsional'nykh narushenii u onkogematologicheskikh bol'nykh. Vestn. Iuzhno-Ural'skogo gos. un-ta. Ser.: Psikhologiia. 2015; 8 (4): 52–60. [in Russian] 20. Мысливцева А.В., Заика В.Г. Влияние химиотерапии на эмоциональное состояние больных с онкологической патологией. Журн. фундаментальной медицины и биологии. 2014; 3: 37–40. / Myslivtseva A.V., Zaika V.G. Vliianie khimioterapii na emotsional'noe sostoianie bol'nykh s onkologicheskoi patologiei. Zhurn. fundamental'noi meditsiny i biologii. 2014; 3: 37–40. [in Russian] 21. Онкология: национальное руководство. Под ред. В.И.Чиссова, М.И.Давыдова. М.: ГЭОТАР-Медиа, 2014. / Onkologiia: natsional'noe rukovodstvo. Pod red. V.I.Chissova, M.I.Davydova. M.: GEOTAR-Media, 2014. [in Russian] 22. Рослякова В.А. Клинико-психопатологическая характеристика депрессивных расстройств непсихотического уровня у больных с опухолями челюстно-лицевой области. Мед. психология. 2012; 7 (1): 85–8. / Rosliakova V.A. Kliniko-psikhopatologicheskaia kharakteristika depressivnykh rasstroistv nepsikhoticheskogo urovnia u bol'nykh s opukholiami cheliustno-litsevoi oblasti. Med. psikhologiia. 2012; 7 (1): 85–8. [in Russian] 23. Русина Н.А. Психологический статус и адаптационные ресурсы онкологических больных. Рос. медико-биологический вестн. им. акад. И.П.Павлова. 2012; 3: 116–23. / Rusina N.A. Psikhologicheskii status i adaptatsionnye resursy onkologicheskikh bol'nykh. Ros. mediko-biologicheskii vestn. im. akad. I.P.Pavlova. 2012; 3: 116–23. [in Russian] 24. Савин А.И., Володин Б.Я. Особенности психогенно обусловленных психических расстройств и психологические характеристики онкологических больных при разных опухолевых локализациях (подход к проблеме). Наука молодых (Eruditio Juvenium). 2015; 3: 82–6. / Savin A.I., Volodin B.Ia. Osobennosti psikhogenno obuslovlennykh psikhicheskikh rasstroistv i psikhologicheskie kharakteristiki onkologicheskikh bol'nykh pri raznykh opukholevykh lokalizatsiiakh (podkhod k probleme). Nauka molodykh (Eruditio Juvenium). 2015; 3: 82–6. [in Russian] 25. Самушия М.А. Психические расстройства у больных злокачественными новообразованиями органов женской репродуктивной системы (клиника, эпидемиология, терапия). Дис. ... д-ра мед. наук. М., 2014. / Samushiia M.A. Psikhicheskie rasstroistva u bol'nykh zlokachestvennymi novoobrazovaniiami organov zhenskoi reproduktivnoi sistemy (klinika, epidemiologiia, terapiia). Dis. ... d-ra med. nauk. M., 2014. [in Russian] 26. Самушия М.А., Мясникова Л.К. Вальдоксан (агомелатин) в терапии депрессивных расстройств у пациентов с онкологическими заболеваниями органов женской репродуктивной системы. Психические расстройства в общей медицине. 2012; 3: 16–20. / Samushiia M.A., Miasnikova L.K. Val'doksan (agomelatin) v terapii depressivnykh rasstroistv u patsientov s onkologicheskimi zabolevaniiami organov zhenskoi reproduktivnoi sistemy. Mental Disorders in General Medicine. 2012; 3: 16–20. [in Russian] 27. Сенина В.С. Психологический статус онкобольного пациента. Молодой ученый. 2017; 48: 164–8. / Senina V.S. Psikhologicheskii status onkobol'nogo patsienta. Molodoi uchenyi. 2017; 48: 164–8. [in Russian] 28. Сидоров П.И., Совершаева Е.П. Синергетическая биопсихосоциодуховная концепция социальной эпидемиологии онкологических заболеваний. Экология человека. 2015; 4: 47–57. / Sidorov P.I., Sovershaeva E.P. Sinergeticheskaia biopsikhosotsiodukhovnaia kontseptsiia sotsial'noi epidemiologii onkologicheskikh zabolevanii. Ekologiia cheloveka. 2015; 4: 47–57. [in Russian] 29. Смулевич А.Б. Психические расстройства в клинической практике. М., 2011. / Smulevich A.B. Psikhicheskie rasstroistva v klinicheskoi praktike. M., 2011. [in Russian] 30. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Психические расстройства в онкологии (результаты многоцентровой программы СИНТЕЗ). Психические расстройства в общей медицине. 2009; 1: 4–11. / Smulevich A.B., Andriushchenko A.V., Beskova D.A. Psikhicheskie rasstroistva v onkologii (rezul'taty mnogotsentrovoi programmy SINTEZ). Mental Disorders in General Medicine. 2009; 1: 4–11. [in Russian] 31. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Результаты исследования РИТМ: терапия непсихотических депрессий Вальдоксаном. Психиатрия и психофармакотерапия. 2010; 4: 4–12. / Smulevich A.B., Andriushchenko A.V., Beskova D.A. Rezul'taty issledovaniia RITM: terapiia nepsikhoticheskikh depressii Val'doksanom. Psychiatry and Psychopharmacotherapy. 2010; 4: 4–12. [in Russian] 32. Солопова А.Г., Идрисова Л.Э., Макацария А.Д., Чуканова Е.М. Психосоматика и психотерапия как ключ к эффективной реабилитации онкогинекологических больных. Акуш., гинекол. и репрод. 2017; 11 (1): 65–73. DOI: 10.17749/23137347.2017.11.1.065-073 / Solopova A.G., Idrisova L.E., Makatsariia A.D., Chukanova E.M. Psikhosomatika i psikhoterapiia kak kliuch k effektivnoi reabilitatsii onkoginekologicheskikh bol'nykh. Akush., ginekol. i reprod. 2017; 11 (1): 65–73. DOI: 10.17749/23137347.2017.11.1.065-073 [in Russian] 33. Солопова А.Г., Табакман Ю.Ю., Идрисова Л.Э., Сдвижков А.М. Реабилитация онкогинекологических больных. Взгляд на проблему. Акуш., гинекол. и репрод. 2015; 9 (4): 46–54. / Solopova A.G., Tabakman Iu.Iu., Idrisova L.E., Sdvizhkov A.M. Reabilitatsiia onkoginekologicheskikh bol'nykh. Vzgliad na problemu. Akush., ginekol. i reprod. 2015; 9 (4): 46–54. [in Russian] 34. Тарабрина Н.В. Посттравматический стресс у больных угрожающими жизни (онкологическими) заболеваниями. Консультативная психология и психотерапия. 2014; 1. / Tarabrina N.V. Posttravmaticheskii stress u bol'nykh ugrozhaiushchimi zhizni (onkologicheskimi) zabolevaniiami. Konsul'tativnaia psikhologiia i psikhoterapiia. 2014; 1. [in Russian] 35. Федотов И.А. и др. Лечение клиентов с суицидальным поведением в различных психотерапевтических модальностях (обзор литературы). Наука молодых (Eruditio Juvenium). 2015; 1: 116–26. / Fedotov I.A. i dr. Lechenie klientov s suitsidal'nym povedeniem v razlichnykh psikhoterapevticheskikh modal'nostiakh (obzor literatury). Nauka molodykh (Eruditio Juvenium). 2015; 1: 116–26. [in Russian] 36. Черепкова Е.В. Клиника и динамика психических расстройств у онкобольных с раком различных локализаций: Автореф. дис. … канд. мед. наук. Новосибирск, 2002; 26. / Cherepkova E.V. Klinika i dinamika psikhicheskikh rasstroistv u onkobol'nykh s rakom razlichnykh lokalizatsii: Avtoref. dis. … kand. med. nauk. Novosibirsk, 2002; 26. [in Russian] 37. Шафигуллин М.Р. Терапия нозогенных реакций у больных раком желудка. Психические расстройства в общей медицине. 2009; 1: 38–45. / Shafigullin M.R. Terapiia nozogennykh reaktsii u bol'nykh rakom zheludka. Mental Disorders in General Medicine. 2009; 1: 38–45. [in Russian] 38. Ширяев О.Ю., Васильева Ю.Е. Психоонкология – наука нашего времени. В сб.: Психология и педагогика XXI века: теория, практика и перспективы. ФГБОУ ВПО «Чувашский государственный университет им. И.Н.Ульянова»; Харьковский национальный педагогический университет имени Сковороды; Актюбинский региональный государственный университет им. К.Жубанова; ООО «Центр научного сотрудничества "Интерактив плюс"». 2016; 455–60. / Shiriaev O.Iu., Vasil'eva Iu.E. Psikhoonkologiia – nauka nashego vremeni. V sb.: Psikhologiia i pedagogika XXI veka: teoriia, praktika i perspektivy. FGBOU VPO "Chuvashskii gosudarstvennyi universitet im. I.N.Ul'ianova"; Khar'kovskii natsional'nyi pedagogicheskii universitet imeni Skovorody; Aktiubinskii regional'nyi gosudarstvennyi universitet im. K.Zhubanova; OOO "Tsentr nauchnogo sotrudnichestva "Interaktiv plius". 2016; 455–60. [in Russian] 39. Щербакова И.В., Барденштейн Л.М., Аверьянова С.В. Подходы к диагностике и лечению тревожных и депрессивных расстройств у онкологических больных. Рос. мед. журн. 2015; 21 (2): 46–50. / Shcherbakova I.V., Bardenshtein L.M., Aver'ianova S.V. Podkhody k diagnostike i lecheniiu trevozhnykh i depressivnykh rasstroistv u onkologicheskikh bol'nykh. Ros. med. zhurn. 2015; 21 (2): 46–50. [in Russian] 40. Ahn MH, Park S, Lee HB et al. Suicide in cancer patients within the first year of diagnosis. Psychooncology 2015; 24: 601–7. 41. Akechi T, Okamura H, Nakano T et al. Gender differences in factors associated with suicidal ideation in major depression among patients with cancer. Psychooncology 2010; 19: 384–9. 42. Amr YM, Yousef AA. Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J Pain 2010; 26 (5): 381–5. 43. Carvalhoa AF, Sharmac MS, Brunonib AR et al. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom 2016; 85: 270–88. DOI: 10.1159/000447034 44. Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998; 13 (Suppl. 6): S1–S4. 45. Anguiano L, Mayer DK, Piven ML, Rosenstein D. A literature review of suicide in cancer patients. Cancer Nurs 2012; 35: 14–26. 46. Antonova L, Aronson K, Mueller CR. Stress and breast cancer: from epidemiology to molecular biology. Breast Cancer Res 2011; 13: 208. 47. Arimochi H, Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 2006; 541 (1–2): 17–23. 48. Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. Brain Behav Immun 2009; 23: 10–5. 49. Arnold SD, Forman LM, Brigidi BD et al. Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neurooncology 2008; 10: 171–81. 50. Barton DL, Loprinzi CL, Novotny P et al. Pilot evaluation of citalopram for the relief of hot flushes. J Support Oncol 2003; 1: 47–51. 51. Biglia N, Kubatzki F, Sgandurra P et al. Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. Breast J 2007; 13: 490–5. 52. Boesen EH, Boesen SH, Frederiksen K et al. Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: areplicationstudy. J Clin Oncol 2007; 25: 5698–703. 53. Bolton JM, Walld R, Chateau D et al. Risk of suicide and suicide attempts associated with physical disorders: a population-based, balancing score-matched analysis. Psychol Med 2015; 45: 495–504. 54. Breitbart W, Pessin H, Kolva E. Suicide and desire for hastened death in people with cancer. Depression Cancer 2011; Chichester, UK: Wiley-Blackwell; p. 125–50. 55. Breitbart W, Poppito S, Rosenfeld B et al. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. J Clin Oncol 2012; 30 (12): 1304–9. 56. Brietbart W, Rosenfeld B, Pessin H et al. Depression, hopelessness, and the desire for hastened death in terminally ill patients with cancer. JAMA 2000; 284: 2907–11. 57. Buijs C, Mom CH, Willemse PH et al. Venlafaxine versus clonidine for the treatment of hot flushes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009; 115: 573–80. 58. Buoli M, Grassi S, Serati M et al. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 2017; 18: 1373–9. 59. Cabaniols C, Giorgi R, Chinot O et al. Links between private habits, psychological stress and brain cancer: a case-control pilot study in France. J Neurooncol 2011; 103: 307–16, 46. 60. Chia-Ling Lin et al. The Association Between Sleep Disorders and the Risk of Colorectal Cancer in Patients: A Population-based Nested Case – Control Study. DOI: 10.21873/invivo.11513 61. Chida Y, Hamer M, Wardle J et al. Do stressrelated psychosocial factors contribute to cancer incidenceand survival? Nat Clin Pract Oncol 2008; 5: 466–75. 62. Cohen L, Parker PA, Vence L et al. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. Psychosom Med 2011; 73: 218–25. 63. Conwell Y, van Orden K, Caine ED. Suicide in older adults. Psychiatr Clin North Am 2011; 34: 451–68. 64. Corruble E, Belaidi C, Goodwin G. Agomelatine versus escitalopram in major depressive disorders: a randomized double-blind, longterm study focusing on sleep satisfaction and emotional blunting. Eur Psychiat 2011; 26: 2–24. 65. Costantini A, Pompili M, Innamorati M et al. Psychiatric pathology and suicide risk in patients with cancer. J Psychosoc Oncol 2014; 32: 383–95. 66. Stein DJ et al. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50mg/day) versus escitalopram (10–20mg/day) in out-patients with severe generalized anxiety disorder. Eur Neuropsychopharmacol 2018; p. 1–10. https://doi.org/10.1016/j.euroneuro.2018.05.006 67. Spiegel D. Minding the body: Psychotherapy and cancer survival. Br J Health Psychol 2013: 19 (3): 1–21. 68. De Berardis D, Marini S, Fornaro M et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci 2013; 14: 12458–83. 69. De Bodinat C, Guardiola-Lemaitre B, Mocaer E et al. Agomthe first melatonergic antidepressant: discovery, charactand development. Nat Rev Drug Discov 2010; 9: 628–42. 70. De Leeuw JRJ, de Graeff A, Ros WJG et al. Prediction of depression 6 months to 3 years after treatment of head and neck cancer. Head Neck 2001; 23: 892–8. 71. Delgado-Guay M, Yennurajalingam S, Parsons H et al. Association between self-reported sleep disturbance and other symptoms in patients with advanced cancer. J Pain Symptom Manag 2011; 41 (5): 819–27. 72. Delgado-Guay M, Parsons H, Li Z et al. Symptom distress in advanced cancer patients with anxiety and depression in a palliative care setting. Support Care Cancer 2009; 17 (5): 573–9. 73. Denaro N, Tomasello L, Russi EG. Cancer and stress: what’s matter? From epidemiology: the psychologist and oncologist point of view. J Cancer Ther Res 2014; 3: 6. http://dx.doi.org/10.7243/2049-7962-3-6 74. Derogatis LR, Morrow GR, Fetting J et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983; 249: 751–7. 75. Di Giannantonio M, Di Iorio G, Guglielmo R et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 2011; 25: 109–14. 76. Di Giannantonio M, Martinotti G. Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol 2012; 22 (Suppl. 3): 505–10. 77. Fang Ch-K, Chang M-Ch, Chen P-J et al. A correlational study of suicidal ideation with psychological distress, depression, and demoralization in patients with cancer. Support Care Cancer 2014; 22: 3165–74. 78. Fang F, Fall K, Mittleman MA et al. Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 2012; 366: 1310–8. 79. Galfin JM, Watkins ER Construal Level, Rumination, and Psychological Distress in Palliative Care. Psycho-Oncology 2012; 21: 680–3. DOI: 10.1002/pon.1948 80. Gargoloff PD, Corral R, Herbst L et al. Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study. Hum Psychopharmacol 2016; 31: 412–8. 81. Gil-Ad I, Zolokov A, Lomnitski L et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancerxenografted mice. Int J Oncol 2008; 33 (2): 277–86. 82. Goodwin G, Rouillon F, Emsley R. Longterm treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months [abstr]. In: 21st European College of Neuropsychopharmacology Congress. Barcelona, Spain. Eur Neuropsychopharmacol 2008; 18: s338–9. 83. Goodwin GM, Emsley R, Rembry S et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 1128–37. 84. Grassi L, Nanni MG, Uchitomi Y, Riba M. Pharmacotherapy of Depression in People with Cancer. In: Kissane D.W., Maj M., Sartorius N. (Eds). Depression and Cancer. John Wiley & Sons, Ltd., 2011; p. 151–76. 85. Guaiana G, Gupta S, Chiodo D et al. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013; 17: CD008851. 86. Haisfield-Wolfe ME, McGuire DB, Soeken K, De Forge BR. Prevalence and correlates of depression among patients with head and neck cancer: a systematic review of implications for research. Oncol Nurs Forum 2009; 36 (3): E107–25. 87. Hart CL, Hole DJ, Lawlor DA et al. Effect of conjugal bereavement on mortality of the bereaved spouse in participants of the Renfrew/Paisley Study. J Epidemiol Community Health 2007; 61 (5): 455–60. 88. Higgins SC, Pilkington GJ. The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res 2010; 30 (2): 391–7. 89. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 2000; 18: 893–903. 90. Bryant HM, Christensen AJ, Karnell LH, Funk GF. Psychological Factors Associated With Head and Neck Cancer Treatment and Survivorship: Evidence and Opportunities for Behavioral Medicine. J Consulting Clin Psychol 2013; 81 (2): 299–317. 91. Illan J, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64. 92. Innamorati M, Pompili M, Di Vittorio C et al. Suicide in the old elderly: Results from one Italian county. Am J Ger Psychiatry 2014; 22: 1158–67. 93. Irani J, Salomon L, Oba R et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147–54. 94. Jacobsen PB, Donovan KA. Psychological co-morbidities of cancer. In: Psychological comorbidities of physical illness: a behavioral medicine perspective. Springer Science + Business Media, LLC, 2011; p. 163–206. 95. Jahchcm NS, Dudley JТ, Mazur PК et al. A drug repositioning approach identifi es tricyclic antidepressants as inhibitors of small cell lungcancer and other neuroendocrine tumors. Cancer Discov 2013; 3 (12): 1364–77. 96. Jakobsen G, Engstrom M, Fayers P et al. Sleep quality with WHO Step III opioid use for cancer pain. BMJ Support Palliat Care 2018. https://doi.org/10.1136/bmjspcare-2017-001399 97. Jin Y, Desta Z Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30–9. 98. Johnson TV, Garlow SJ, Brawley OW, Master VA. Peak window of suicides occurs within the first month of diagnosis: implications for clinical oncology. Psychooncology 2012; 21: 351–6. 99. Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109–20. 100. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: 693. 101. Kennedy SH. Agomelatine. Efficacy at each phase of antidepressant treatment. CNS Drugs 2009; 23 (Suppl. 2): 41–7. 102. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100. 103. Kimmick GG, Lovato J, McQuellon R et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flushes in women with early stage breast cancer taking tamoxifen. Breast J 2006; 12: 114–22. 104. Kissane DW, Clarke DM, Street AF. Demoralization syndrome - a relevant psychiatric diagnosis for palliative care. J Palliat Care 2001; 17: 12–21. 105. Kissane DW, Grabsch B, Love A et al. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust NZJ Psychiatry 2004; 38: 320–6. 106. Kissane DW, Levin T, Hales S et al. Psychotherapy for Depression in Cancer and Palliative Care. In: D.W. Kissane, M. Maj, N. Sartorius (Eds). Depression and Cancer. John Wiley & Sons, Ltd., 2011; p. 177–206. 107. Koesters M, Guaiana G, Cipriani A et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013; 203: 179–87. 108. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007; 67: 1657–63. 109. Lamkin DM, Sloan EK, Patel AJ et al. Chronic stress enhances progression of acute lymphoblastic leukemia via beta-adrenergic signaling. Brain Behav Immun 2012; 26: 635–41. 110. Larid B, Colvin L, Fallon M. Management of cancer pain: basic prin ciples and neuropathic cancer pain. Eur J Cancer 2008; 44 (8): 1078–82. 111. Lash TL, Pedersen L, Cronin-Fenton D et al. Tamoxifen’s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 2008; 99: 616–21. 112. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32. 113. Leung YW, Li M, Devins G et al. Routine screening for suicidal intention in patients with cancer. Psychooncology 2013; 22: 2537–45. 114. Lichtenthel WG. Do rate of mental disorders and existential distress among advanced stage cancer patient increase as death approaches? Psycho-Oncology 2009; 18 (1): 50–61. 115. Lin HC, Wu CH, Lee HC. Risk factors for suicide following hospital discharge among patients with cancer. Psychooncology 2009; 18: 1038–44. 116. Lin Y, Wang C, Zhong Y et al. Striking life events associated with primary breast cancer susceptibility in women: a meta-analysis study. J Exper Clin Cancer Res 2013; 32 (1): 53. 117. Litofsky NS, Farace E, Anderson F et al. Depression in patients with highgrade glioma: results of the glioma outcomes project. Neurosurgery 2004; 54: 358–67. 118. Lloyd-Williams M, Shiels C, Taylor F, Dennis M. Depression – an independent predictor of early death in patients with advanced cancer. J Affect Dis 2009; 113: 127–32. 119. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47. 120. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flushes. J Clin Oncol 2002; 20: 1578–83. 121. Lu D, Andersson TM, Fall K et al. Clinical Diagnosis of Mental Disorders Immediately Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden. JAMA Oncol 2016; 2 (9): 1188–96. 122. Lu D, Fall K, Sparen P et al. Suicide and suicide attempt after a cancer diagnosis among young individuals. Ann Oncology 2013; 24: 3112–7. 123. Lutgendorf SK, Sood AK. Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med 2011; 73: 724–30. 124. Madeira N, Albuquerque E, Santos T et al. Death ideation in cancer patients: contributing factors. J Psychosoc Oncol 2011; 29: 636–42. 125. Mallet J, Huillard O, Goldwasser F et al. Mental disorders associated with recent cancer diagnosis: Results from a nationally representative survey. Eur J Cancer 2018; p. 10–8. 126. Martinotti G, Sepede G, Gambi F et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol 2012; 32: 487–91. 127. Massie MJ, Lloyd-Williams M, Irving G, Miller K. The Prevalence of Depression in People with Cancer. In: D.W.Kissane, M.Maj, N.Sartorius (Eds). Depression and Cancer. John Wiley & Sons, Ltd., 2011; p. 1–36. 128. Mc Gregor BA, Antoni MH. Psychological intervention and health outcomes among women treated for breast cancer: a review of stress pathways and biological mediators. Brain Behav Immun 2009; 23: 159–60. 129. McGinty EE, Zhang Y, Guallar E et al. Cancer incidence in a sample of Maryland residents with serious mental illness. Psychiatr Serv 2012; 63: 714–7. 130. Mercadante S, Aielli F, Adile C et al. Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manag 2015; 50 (6):786–92. 131. Montejo A, Majadas S, Rizvi SJ et al. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011; 26: 537–42. 132. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283–91. 133. Musselman DL, Miller AH, Royster EB, McNutt MD. Biology of Depression and Cytokines in Cancer. In: D.W.Kissane, M.Maj, N.Sartorius (Eds). Depression and Cancer. John Wiley & Sons, Ltd., 2011; p. 51–80. 134. Musuuza JS, Sherman ME, Knudsen KJ et al. Analyzing excess mortality from cancer among individuals with mental illness. Cancer 2013; 119: 2469–76. 135. Mystakidou K, Parpa E, Tsilika E et al. How is sleep quality affected by the psychological and symptom distress of advanced cancer patients? Palliat Med 2009; 23 (1): 46–53. 136. Mystakidou K, Parpa E, Tsilika E et al. Sleep quality in advanced cancer patients. J Psychosom Res 2007; 62 (5): 527–33. 137. Nakash O, Levav I Aguilar-Gaxiola S et al. Comorbidity of common mental disorders with cancer and their treatment gap: findings from the World Mental Health Surveys. Psychooncology 2014; 23: 40–51. 138. Nelson EL, Wenzel LB, Osann K et al. Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]. Clin Cancer Res 2008; 14: 2111–8. 139. Ng CG, Boks MP, Zainal NZ, de Wit NJ. The prevalence and pharmacotherapy of depression in cancer patients. J Affect Dis 2011; 131 (1–3): 1–7. 140. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73. 141. Onitilo AA, Nietert PJ, Egede LE. Effect of depression on allcause mortality i adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 2006; 28 (5): 396–402. 142. Otte JL, Carpenter JS, Manchanda S et al. Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained? Cancer Med 2015; 4 (2): 183–200. 143. Palesh O, Aldridge-Gerry A, Zeitzer JM et al. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep 2014; 37 (5): 837–42. 144. Palesh OG, Roscoe JA, Mustian KM et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010; 28 (2): 292–8. 145. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F et al. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res 2010; 19: 45–54. 146. Perini G, Grigoletti L, Hanife B et al. Cancer mortality among psychiatric patients treated in a community-based system of care: a 25-year case register study. Soc Рsychiatry Psychiatr Epid 2014; 49: 693–701. 147. Pillai Sh, Lichtman AH, Abbas AK. Basic Immunology: Functions and Disorders of the Immune System. London: Elsevier, 2015. 148. Power D, Kelly S, Gilsenan J et al. Suitable screening tests for the cognitive impairment and depression in the terminally ill – a prospective prevalence study. Palliat Med 1993; 7: 213–8. 149. Prevalence associations and adequacy of treatment of major depression in patients with cancer. A cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry 2014; 1 (5). https: //www.researchgate.net/publication/265129372 150. Quera-Salva MA, Hajak G, Philip P et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011; 26: 252–62. 151. Rafanelli C, Guidi J, Gostoli S et al. Subtyping demoralization in the medically ill by cluster analysis. Eur J Psychiatry 2013; 27: 7–17. 152. Randall JR, Walld R, Finlayson G et al. Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatr 2014; 59 (10): 531–8. 153. Reznik AM, Mironychev GN, Arbuzov AL et al. Application of cipramil for patients with gastrointestinal cancer and depression. Zhumal Nevrologii i Psikhiatrii im. S.S.Korsakova 2004; 104 (9): 39–42. 154. Rhondali W, Perceau E, Berthiller J et al. Frequency of depression among oncology outpatients and association with other symptoms. Support. Care Cancer 2012; 20 (11): 2795–802. 155. Robson A, Scrutton F, Wilkinson L, MacLeod F. The risk of suicide in patients with cancer: a review of the literature. Psychooncology 2010; 19: 1250–8. 156. Russ TC, Stamatakis E, Hamer M et al. Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies. BMJ 2012; 345: e4933. DOI: 10.1136/bmj.e4933 157. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; 17 (4): CD005454. 158. San Larranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008; 23: 396–402. 159. Sapetti A. Agomelatine: an antidepressant without deterioration of sexual response. J Sex Marital Ther 2012; 38: 190–7. 160. Sateia MJ, Lang BJ. Sleep and cancer: recent developments. Curr Oncol Rep 2008; 10 (4): 309–18. 161. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001; 19 (3): 895–908. 162. Sephton SE, Dhabhar FS, Keuroghlian AS et al. Depression, cortisol, and suppressed cell- mediated immunity in metastatic breast cancer. Brain Behav Immun 2009; 23: 1148–55. 163. Soo H, Sherman KA. Rumination, Psychological Distress and Post-Traumatic Growth in Women Diagnosed with Breast Cancer. Psycho-Oncology 2015; 24: 70–9. DOI: 10.1002/pon.3596 164. Stahl SM, Fava M, Trivedi MH et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010; 71: 616–26. 165. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758–64. 166. Stearns V, Slack R, Greep N et al. Paroxetine is an effective treatment for hot flushes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23: 6919–30. 167. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561–6. 168. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol 2013; 28: 151–9. 169. Susanne Kuhnt et al. Twelve-Month and Lifetime Prevalence of Mental Disorders in Cancer Patients, Psychotherapy Psychosomatics 2016; 85 (5): 289–96. DOI: 10.1159/000446991 170. Tay L, Tan K, Diener E, Gonzalez E. Social relations, health behaviors, and health outcomes: a survey and synthesis. Appl Psychol Health Well Being 2013; 5 (1): 28–78. 171. Taylor D, Sparshatt A, Varma S et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014; 348: g1888. 172. The Relationship Between Psychosocial Risk Factors and Health Outcomes of Chronic Diseases: A Review of the Evidence for Cancer and Cardiovascular Diseases. Pikhart H, Pikhartova J. Copenhagen: WHO Regional Office for Europe, 2015. 173. Thomsen DK, Jensen AB, Jensen T et al. Rumination, Reflection and Distress: an 8-Month Prospective Study of Colon-Cancer Patients. Cognitive Ther Res 2013; 37: 1262–8. DOI: 10.1007/s10608-013-9556-x 174. Trevino KM, Balboni M, Zollfrank A et al. Negative religious coping as a correlate of suicidal ideation in patients with advanced cancer. Psychooncology 2014; 23: 936–45. 175. Norman TR, Olver JS. Agomelatine for depression: expanding the horizons? Expert Opin Pharmacother 2019. DOI: 10.1080/14656566. 2019.1574747 176. Tsokos G, Grammatikos A. Immunodeficiency and autoimmunity. Trends Mol Med 2012; 18 (2): 101–8. DOI:10.1016/j.molmed. 2011.10.005 177. Vyssoki B, Gleiss A, Rockett IR et al. Suicide among 915,303 Austrian cancer patients: who is at risk? J Affect Dis 2015; 175: 287–91. 178. Williams WP, McLin DE, Dressman MA, Neubauer DN. Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders. DOI: 10.1002/phar.1822 179. Yu LS, Chojniak R, Borba MA et al. Prevalence of anxiety in patients awaiting diagnostic procedures in an oncology center in Brazil. Psychooncology 2011; 20 (11): 1242–5. 180. Zajecka J, Schatzberg A, Stahl S et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010; 30: 135–44.